Sona Nanotech Inc
CNSX:SONA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Sona Nanotech Inc
Operating Income
Sona Nanotech Inc
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Sona Nanotech Inc
CNSX:SONA
|
Operating Income
-CA$3.2m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
|
Abcellera Biologics Inc
NASDAQ:ABCL
|
Operating Income
-$217.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Replicel Life Sciences Inc
XTSX:RP
|
Operating Income
-CA$39.4k
|
CAGR 3-Years
37%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Innovotech Inc
XTSX:IOT
|
Operating Income
CA$23.9k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-16%
|
CAGR 10-Years
N/A
|
|
Sona Nanotech Inc
Glance View
Sona Nanotech, Inc. is a nanotechnology life sciences company, which engages in the development and manufacture of rod-shaped gold nanoparticles. The company is headquartered in Halifax, Nova Scotia and currently employs 8 full-time employees. The company went IPO on 2018-10-04. The firm is engaged in the research and development of its technology for use in multiplex diagnostic testing platforms and biomedical applications. Its core technology is a rod-shaped nanoparticle manufactured at scale with surfactants that allow the production of two different product lines (Gemini and Omni) for use in both in-vitro and in-vivo applications, such as lateral flow diagnostics and cell imaging respectively. The firm's gold nanorod particles are manufactured without the use of CTAB (cetyltrimethylammonium), eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. The firm also offers development services to help lateral flow producers create new lateral flow tests and improve existing tests for their product iteration.
See Also
What is Sona Nanotech Inc's Operating Income?
Operating Income
-3.2m
CAD
Based on the financial report for Jan 31, 2026, Sona Nanotech Inc's Operating Income amounts to -3.2m CAD.
What is Sona Nanotech Inc's Operating Income growth rate?
Operating Income CAGR 5Y
24%
Over the last year, the Operating Income growth was -5%. The average annual Operating Income growth rates for Sona Nanotech Inc have been -13% over the past three years , 24% over the past five years .